ACP-105 for Selective Anabolic Activity — SARMs

Overview

ACP-105 is a non-steroidal selective androgen receptor modulator developed by Acadia Pharmaceuticals as part of their androgen receptor research program. It is classified as a partial androgen receptor agonist, meaning it activates the AR to a lesser maximal extent than full agonists like testosterone or DHT, but with significantly enhanced tissue selectivity. In preclinical studies using castrated rat models, ACP-105 demonstrated approximately 67% of the anabolic activity of testosterone on levator ani muscle weight while producing only minimal effects on prostate and seminal vesicle weights. This favorable anabolic-to-androgenic ratio suggests strong tissue selectivity, though the reduced maximal efficacy means it would likely produce less dramatic muscle-building effects compared to more potent SARMs like RAD-140 or LGD-4033. Very limited published research exists on ACP-105, with the primary data coming from Acadia Pharmaceuticals patent filings and a small number of preclinical publications. No human pharmacokinetic, safety, or efficacy studies have been conducted. The compound has not entered clinical development for any indication. ACP-105 represents one of the least-studied SARMs available on the gray market, with almost all usage information derived from anecdotal reports rather than scientific data. Its partial agonist pharmacology may theoretically result in milder HPG axis suppression compared to full agonist SARMs, but this has not been confirmed in human studies. The compound is NOT FDA-approved for any indication, has no IND application, and is prohibited by WADA. Use in humans constitutes uncharted experimentation with an extremely limited evidence base.

Indications

• Preclinical investigation of tissue-selective partial AR agonism
• Research into anabolic compounds with reduced androgenic side effect profiles
• Basic research compound for AR pharmacology studies
• Potential investigation for osteoporosis (preclinical rationale only)
• No clinical development initiated for any indication

Mechanism of Action

ACP-105 administered orally with presumed reasonable bioavailability based on non-steroidal SARM class characteristics. No published pharmacokinetic parameters. Dosing frequency based on speculation

Dosing

Evidence Grade

GRADE D

Safety & Contraindications

• NOT FDA-approved — no human studies of any kind
• Extremely limited published research — mostly patent data
• Unknown human pharmacokinetics — no half-life, bioavailability, or clearance data
• Partial agonist — theoretically milder suppression but unconfirmed in humans
• No safety data in humans — adverse effect profile entirely unknown
• WADA prohibited substance
• Gray-market only — no quality standards or pharmaceutical production
• Unknown drug interaction profile
• Unknown hepatotoxicity potential
• No established dosing protocol — all doses are speculative